14
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Fyn-phosphorylated PIKE-A binds and inhibits AMPK signaling, blocking its tumor suppressive activity

      research-article

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          The AMP-activated protein kinase, a key regulator of energy homeostasis, has a critical role in metabolic disorders and cancers. AMPK is mainly regulated by cellular AMP and phosphorylation by upstream kinases. Here, we show that PIKE-A binds to AMPK and blocks its tumor suppressive actions, which are mediated by tyrosine kinase Fyn. PIKE-A directly interacts with AMPK catalytic alpha subunit and impairs T172 phosphorylation, leading to repression of its kinase activity on the downstream targets. Mutation of Fyn phosphorylation sites on PIKE-A, depletion of Fyn, or pharmacological inhibition of Fyn blunts the association between PIKE-A and AMPK, resulting in loss of its inhibitory effect on AMPK. Cell proliferation and oncogenic assays demonstrate that PIKE-A antagonizes tumor suppressive actions of AMPK. In human glioblastoma samples, PIKE-A expression inversely correlates with the p-AMPK levels, supporting that PIKE-A negatively regulates AMPK activity in cancers. Thus, our findings provide additional layer of molecular regulation of the AMPK signaling pathway in cancer progression.

          Related collections

          Author and article information

          Journal
          Cell Death Differ
          Cell Death Differ
          Cell Death and Differentiation
          Nature Publishing Group
          1350-9047
          1476-5403
          January 2016
          22 May 2015
          : 23
          : 1
          : 52-63
          Affiliations
          [1 ] Department of Pathology and Laboratory Medicine, Emory University School of Medicine , Atlanta, 30322 GA, USA
          [2 ] Department of Physiology, The University of Oklahoma Health Sciences Center , Oklahoma City, 73104 OK, USA
          [3 ] Department of Hematology and Medical Oncology, Emory University School of Medicine , Atlanta, 30322 GA, USA
          [4 ] Winship Cancer Institute, Emory University School of Medicine , Atlanta, 30322 GA, USA
          [5 ] Department of Pathology and Lab Medicine, Harvard Medical School and Children's Hospital , Boston, 02115 MA, USA
          Author notes
          [* ] Department of Pathology and Laboratory Medicine, Emory University School of Medicine , Room 141, Whitehead Building, 615 Michael Street, Atlanta, 30322 GA, USA. Tel: +404 712 2814; Fax: +404 712 2979; E-mail: kye@ 123456emory.edu
          Author information
          http://orcid.org/0000-0002-2787-9575
          Article
          PMC4815978 PMC4815978 4815978 cdd201566
          10.1038/cdd.2015.66
          4815978
          26001218
          5fa17cce-df3d-49db-9b69-12c0498a4a2a
          Copyright © 2016 Macmillan Publishers Limited
          History
          : 15 January 2015
          : 16 April 2015
          : 22 April 2015
          Categories
          Original Paper

          Comments

          Comment on this article